missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ SFXN4 Polyclonal Antibody

Description
This target displays homology in the following species: Human: 100%.
Sideroflexin 4 (SFXN4) is a gene primarily associated with mitochondrial functionality and disease. It encodes a protein that is crucial for the assembly of complex I within mitochondria, a critical component of the electron transport chain. Mutations in SFXN4 can result in mitochondrial diseases due to its pivotal role in this process. Interestingly, SFXN4 belongs to the sideroflexin family, traditionally known for amino acid transport, indicating a functional evolution to support mitochondrial assembly. In the context of cancer, specifically ovarian cancer, SFXN4 is involved in the synthesis of iron-sulfur clusters (Fe-S), which are essential for cell growth and division. Inhibition of SFXN4 disrupts Fe-S biogenesis, highlighting its potential as a target for anti-cancer therapy. Additionally, SFXN4's expression and function have been correlated with immune pathways in hepatocellular carcinoma, suggesting broader implications in cancer biology. Knockdown studies and natural mutations demonstrate SFXN4's role in mitochondrial diseases, including macrocytic anemia observed in zebrafish models and implications in human mitochondriopathy.
Specifications
Specifications
| Antigen | SFXN4 |
| Applications | Western Blot |
| Classification | Polyclonal |
| Concentration | 0.5 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 2% sucrose and 0.09% sodium azide |
| Gene | SFXN4 |
| Gene Accession No. | Q6P4A7 |
| Gene Alias | BCRM1; Breast cancer resistance marker 1; COXPD18; SFXN4; sideroflexin 4; sideroflexin-4 |
| Gene Symbols | SFXN4 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?